Physician profile
Robert J Williams
NPI 1548202401
$2,138.83
in general payments reported to CMS, 2019-2025
25 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $136 · 2020: $191 · 2021: $277 · 2022: $289 · 2023: $341 · 2024: $461 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,247.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $391.32 | 2023-2025 | Minimed 780g, Interstim |
| Pfizer INC. | $287.25 | 2019-2024 | |
| Abbvie INC. | $287.00 | 2022-2025 | Qulipta, Ubrelvy |
| Abbott Laboratories | $244.92 | 2021-2024 | Mitraclip |
| Amgen INC. | $228.64 | 2019-2025 | Repatha |
| Lilly USA, LLC | $110.21 | 2020-2025 | Zepbound, Mounjaro |
| Biohaven Pharmaceutical Holding Company LTD. | $82.89 | 2022 | |
| Glaxosmithkline, LLC. | $70.75 | 2023-2025 | Trelegy Ellipta |
| Biohaven Pharmaceuticals, INC. | $49.73 | 2021 | |
| Melinta Therapeutics, LLC | $45.38 | 2021 | |
| Baxter Healthcare | $43.88 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $41.70 | 2022-2024 | Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $41.30 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $40.79 | 2022-2023 | Qelbree |
| Upsher-Smith Laboratories LLC | $33.01 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $24.58 | 2025 | |
| Athena Bioscience, LLC | $20.75 | 2023 | Qdolo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.25 | 2025 | Caplyta |
| Allergan, INC. | $17.21 | 2020 | |
| Biogen, INC. | $15.98 | 2021 | |
| Conmed Corporation | $13.41 | 2023 | Airseal |
| Teva Pharmaceuticals USA, INC. | $13.02 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $12.96 | 2022 | |
| Phathom Pharmaceuticals, INC. | $4.90 | 2025 | Voquezna |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.